Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.
Stimulating human programmed cell death protein 1 (PD-1), a checkpoint inhibitory receptor, with peresolimab may be a viable way to treat autoimmune diseases, according to a study by Tuttle et al. In the study, patients with active rheumatoid arthritis (RA) who were treated with peresolimab experienced greater improvements in disease activity than those who received placebo.
An in-person poster hall and networking lounges are among the highlights attendees can expect at ACR Convergence 2023 in San Diego, Nov. 10–15.
Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.
With an influx of new faces in the 118th Congress, Government Affairs Committee Chair Christina Downey, MD, notes that now is a great time to establish a relationship with your member of Congress and help them understand the day-to-day of what it takes to take care of patients.
Value-based care in rheumatology continues to evolve, and rheumatologists can stay active with advocacy efforts behind value-based care and other government relations initiatives.
Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…
A study found that litifilimab, a humanized monoclonal antibody that binds blood dendritic cell antigen 2, may be effective for the treatment of patients with active cutaneous lupus erythematosus. The treatment successfully reduced skin disease activity in patients at 16 weeks compared with placebo.
In January, Cecilia Pilar Chung, MD, MPH, began her new appointment as director of the Division of Rheumatology at the University of Miami. Previously, Dr. Chung was an associate professor of medicine at Vanderbilt University, Nashville, Tenn., for more than 10 years. At Vanderbilt, Dr. Chung built a strong research portfolio, focusing on the comparative…
As ACR Open Rheumatology (ACROR) enters its fifth year, its founding editors in chief are looking back on the journal’s accomplishments and forward to ushering in a new era, beginning with a search for their successors. Patricia Katz, PhD, professor of medicine and health policy at the University of California, San Francisco (UCSF), and Edward…